Whole-Genome Sequencing of Pigeonpea: Requirement, Background History, Current Status and Future Prospects for Crop Improvement

Despite of being a very important crop, pigeonpea did not have genomic resources until 2005. Pigeonpea Genomics Initiative (PGI) supported by Indian Council of Agricultural Research (ICAR) under Indo-US Agriculture Knowledge Initiative was the first major initiative that delivered first set of molecular markers in large numbers, first set of mapping populations, first set of transcriptome assemblies, etc. Subsequently, two consortia—1) International Initiative for Pigeonpea Genomics (IIPG), led by International Crops Research Institute for the Semi-Arid Tropics (ICRISAT) and 2) Led by National Research Centre on Plant Biotechnology (NRCPB)—delivered two draft genome assemblies for Asha (ICPL 87119) variety. In summary, all these genomic resources transformed pigeonpea from an ‘orphan crop’ to ‘genomics resources-rich crop’. After publication of draft genome sequences, a detailed plan was developed to utilize draft genome information for pigeonpea improvement. This plan in the form of a proposal was approved by Ministry of Agriculture, Government of India and United States Agency for International Development (USAID)—India. In addition to this major project, two additional projects were funded by Department of Biotechnology, Government of India. All these efforts have established high-density genotyping platforms such as genotyping by sequencing (GBS) and ​‘Axiom® CajanusSNP Array’, produced the first generation HapMap, generated whole-genome re-sequencing data of >400 pigeonpea lines, evaluated several mapping populations for desired traits, established marker–trait association for several traits of interest to breeders and also identified best-performing lines. Additionally, multi-parent advance generation inter-cross (MAGIC) and nested association mapping (NAM) populations are being developed. With the availability of above-mentioned information, next few years will be witnessing application of genomics-assisted breeding for pigeonpea improvement. It is anticipated that improved pigeonpea lines developed through genomics interventions will reach to farmers’ fields and elevate the game towards pulse sufficiency for poor farmers in arid and semi-arid regions of the world in near future

Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease

Background: Experimental and clinical data suggest that reducing inflammation without affecting lipid levels may reduce the risk of cardiovascular disease. Yet, the inflammatory hypothesis of atherothrombosis has remained unproved. Methods: We conducted a randomized, double-blind trial of canakinumab, a therapeutic monoclonal antibody targeting interleukin-1β, involving 10,061 patients with previous myocardial infarction and a high-sensitivity C-reactive protein level of 2 mg or more per liter. The trial compared three doses of canakinumab (50 mg, 150 mg, and 300 mg, administered subcutaneously every 3 months) with placebo. The primary efficacy end point was nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death. RESULTS: At 48 months, the median reduction from baseline in the high-sensitivity C-reactive protein level was 26 percentage points greater in the group that received the 50-mg dose of canakinumab, 37 percentage points greater in the 150-mg group, and 41 percentage points greater in the 300-mg group than in the placebo group. Canakinumab did not reduce lipid levels from baseline. At a median follow-up of 3.7 years, the incidence rate for the primary end point was 4.50 events per 100 person-years in the placebo group, 4.11 events per 100 person-years in the 50-mg group, 3.86 events per 100 person-years in the 150-mg group, and 3.90 events per 100 person-years in the 300-mg group. The hazard ratios as compared with placebo were as follows: in the 50-mg group, 0.93 (95% confidence interval [CI], 0.80 to 1.07; P = 0.30); in the 150-mg group, 0.85 (95% CI, 0.74 to 0.98; P = 0.021); and in the 300-mg group, 0.86 (95% CI, 0.75 to 0.99; P = 0.031). The 150-mg dose, but not the other doses, met the prespecified multiplicity-adjusted threshold for statistical significance for the primary end point and the secondary end point that additionally included hospitalization for unstable angina that led to urgent revascularization (hazard ratio vs. placebo, 0.83; 95% CI, 0.73 to 0.95; P = 0.005). Canakinumab was associated with a higher incidence of fatal infection than was placebo. There was no significant difference in all-cause mortality (hazard ratio for all canakinumab doses vs. placebo, 0.94; 95% CI, 0.83 to 1.06; P = 0.31). Conclusions: Antiinflammatory therapy targeting the interleukin-1β innate immunity pathway with canakinumab at a dose of 150 mg every 3 months led to a significantly lower rate of recurrent cardiovascular events than placebo, independent of lipid-level lowering. (Funded by Novartis; CANTOS ClinicalTrials.gov number, NCT01327846.

Renal nurses' lived experiences of discussions about sexuality

Renal teams focus predominantly on renal replacement therapy and physical symptom management, rather than psychological issues, such as mental health, body image or self-esteem. This study aims to increase understanding of how renal nurses feel about discussing sexual issues with patients undergoing haemodialysisRD&E staff can access the full-text of this article - click on the Publisher URL and log in with NHS OpenAthens if prompted.Accepted manuscript - 6 month embargo with set statemen